<scp>cIMPACT</scp> ‐ <scp>NOW</scp> update 11: Proposal on adaptation of diagnostic criteria for <scp>IDH</scp> ‐ and <scp>H3</scp> ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors
Comparative Clinical and Imaging‐Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification
P12.59.B CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
BIOS-01. CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
CNS Embryonal Tumor with PLAGL Amplification, a New Tumor in Children and Adolescents: Insights from a Comprehensive MRI Analysis
Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline
CNS neuroblastoma, FOXR2-activated and its mimics: a relevant panel approach for work-up and accurate diagnosis of this rare neoplasm
Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
Challenges in glioblastoma research: focus on the tumor microenvironment
Molecular and clinical diversity in primary central nervous system lymphoma
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly—A Prospective Study
Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study
Rosette‐forming glioneuronal tumours are midline, <i>FGFR1</i>‐mutated tumours
Molecular and clinical diversity in primary central nervous system lymphoma: a LOC Network study
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
Diffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases
Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas
The molecular landscape of ETMR at diagnosis and relapse
PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas
EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma
Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1
cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates
Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14
The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas